BioCardia, Inc.(BCDA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BCDA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BioCardia, Inc. (BCDA), a Healthcare sector company. BCDA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), BioCardia, Inc. reports net income of $-2.3M, free cash flow of $-1.7M. Top institutional holders of BCDA by reported 13-F value include CM Management,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. BCDA trades on the Nasdaq exchange and files with the SEC under CIK 925741. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioCardia, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.3M
Free Cash Flow
Q1 2026
$-1.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-95.7% YoYNet Income
+33.3% YoYOperating Income
+32.8% YoYTotal Assets
-62.0% YoYOp. Cash Flow
+25.3% YoY| Metric | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $58.0K -95.7% | $1.4M +33.2% | $1.0M +600.0% | $145.0K -76.8% | $625.0K +30.5% | $479.0K |
| Net Income | $-7.9M +33.3% | $-11.9M +5.7% | $-12.6M +15.9% | $-15.0M -7.3% | $-14.0M -13.6% | $-12.3M |
| Operating Income | $-8.0M +32.8% | $-11.9M +5.8% | $-12.6M +18.7% | $-15.5M -10.1% | $-14.1M -13.7% | $-12.4M |
| Total Assets | $3.7M -62.0% | $9.8M -37.7% | $15.7M -32.9% | $23.4M +265.0% | $6.4M -52.6% | $13.5M |
| Operating Cash Flow | $-7.9M +25.3% | $-10.6M -1.9% | $-10.4M +16.1% | $-12.4M -11.6% | $-11.1M -27.7% | $-8.7M |
AI Insight: BCDA Financial Trends
BioCardia remains pre-revenue with consistent ~$2M quarterly operating losses and negative cash flow; no clear inflection visible.
• Revenue unchanged at $0M across all eight quarters through Q1 2026; no commercialization progress.
• Operating losses stable at $1–3M per quarter; Q3 2025 showed modest improvement to $-1M before reverting to $-2M.
• Operating cash outflow consistent at $1–3M per quarter; no improvement in cash burn trajectory.
⚠ Equity swung from $-2M (Q1 2025) to $3M (Q3 2025) then back to $-1M (Q1 2026); balance sheet stability unclear.
⚠ No revenue generation after eight quarters; clinical/regulatory pathway progress unknown from financials alone.
AI Insight: BCDA Ratio Trends
Insufficient data to establish meaningful trends; only one profitability metric visible across nine quarters.
• ROA of -96.5% in Q3 2025 indicates severe quarterly losses; remaining quarters lack comparable profitability metrics.
⚠ No operating margin, NPM, ROE, ROIC, or leverage data available to assess operational efficiency or capital structure trends.
Get alerted when BCDA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BioCardia, Inc. including:
Top Institutional Holders of BCDA
CM Management, LLC
$157.3K130,000 shVANGUARD CAPITAL MANAGEMENT LLC
$150.8K124,591 shGEODE CAPITAL MANAGEMENT, LLC
$114.1K94,287 shVANGUARD FIDUCIARY TRUST CO
$80.2K66,270 shCITADEL ADVISORS LLC
$76.7K63,384 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$47.0K38,827 shPingora Partners LLC
$43.2K35,739 shBROWN ADVISORY INC
$43.0K35,538 shXTX Topco Ltd
$29.4K24,270 shCOMMONWEALTH EQUITY SERVICES, LLC
$22.1K18,283 sh
| Fund | Value | Shares |
|---|---|---|
| CM Management, LLC | $157.3K | 130,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $150.8K | 124,591 |
| GEODE CAPITAL MANAGEMENT, LLC | $114.1K | 94,287 |
| VANGUARD FIDUCIARY TRUST CO | $80.2K | 66,270 |
| CITADEL ADVISORS LLC | $76.7K | 63,384 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $47.0K | 38,827 |
| Pingora Partners LLC | $43.2K | 35,739 |
| BROWN ADVISORY INC | $43.0K | 35,538 |
| XTX Topco Ltd | $29.4K | 24,270 |
| COMMONWEALTH EQUITY SERVICES, LLC | $22.1K | 18,283 |
More Healthcare Companies
View all Healthcare →Put BCDA on your watchlist
Track score changes the day BioCardia, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BCDA a good stock to buy?
13F Pro's AI-powered analysis of BioCardia, Inc. (BCDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCDA are available on the BCDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BCDA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioCardia, Inc.'s investment landscape.